Jenburkt Pharmaceuticals Ltd Stock Price Today (NSE: JENBURPH)

Jenburkt Pharmaceuticals Ltd

1141.5517.85 (1.54%)
Market Closed

Fundamental Score

...

Jenburkt Pharmaceuticals Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis

Jenburkt Pharmaceuticals Ltd share price today is 1141.55, down 1.54% on NSE/BSE as of 18 June 2026. Jenburkt Pharmaceuticals Ltd (JENBURPH) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of 506.05 (Cr). The 52-week high for JENBURPH share price is 1410.00 and the 52-week low is 944.00. At a P/E ratio of 15.33x, JENBURPH is currently trading below its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 19.87% and a debt-to-equity ratio of 0.01.

Jenburkt Pharmaceuticals Ltd Share Price Chart — NSE/BSE Historical Performance

No data
High
1245.00
Low
1030.00
Volume
2.7K
Change
+9.69%

Jenburkt Pharmaceuticals Ltd share price chart: 9.69% return over the past month. 52-week high ₹1410.00, 52-week low ₹944.00.

Jenburkt Pharmaceuticals Ltd — Last 10 Trading Days

DateOpenHighLowCloseVolume
1165.151170.951135.001141.551.48K (Cr)
1152.001175.701152.001159.402.37K (Cr)
1160.001179.651150.051151.20775.00 (Cr)
1147.001174.901147.001157.651.72K (Cr)
1179.351179.501152.001158.652.71K (Cr)
1166.601174.901134.401171.401.52K (Cr)
1151.401174.851142.351154.70701.00 (Cr)
1150.401168.901127.051147.05830.00 (Cr)
1140.201168.851140.201155.901.69K (Cr)
1190.001198.551144.001160.351.96K (Cr)

Jenburkt Pharmaceuticals Ltd — Last 12 Months Price History

MonthOpenHighLowCloseChange
1152.001175.701135.001141.55-0.91%
1087.701245.001033.101151.20+5.84%
976.601070.00961.001044.25+6.93%
997.001044.00944.00955.45-4.17%
1056.601099.95981.001004.00-4.98%
1089.001168.901000.001073.40-1.43%
1175.001185.00990.001089.80-7.25%
1299.001317.001140.001167.75-10.10%
1104.801321.00991.201272.90+15.22%
1094.001199.901026.001102.00+0.73%
1290.001308.951074.051095.00-15.12%
1380.001410.001270.001284.00-6.96%

Returns & Performance

Excellent

Return on Equity (ROE)

19.87%

Profit generated per ₹1 of shareholder equity

Excellent

Return on Capital (ROCE)

27.18%

Returns generated on total capital deployed

Excellent

Oper. Profit Margin (5Y Avg)

22.75%

Average operating profit margin over 5 years

Good

Dividend Yield

1.57%

Annual dividend as % of current share price

Jenburkt Pharmaceuticals Ltd Valuation Check

Excellent

Price to Earnings (P/E)

15.33x

Share price ÷ earnings per share. Lower = cheaper

Poor

Industry Avg P/E

31.77x

Average P/E of all peers in this sector

Market-cap Classification
Small-cap
Higher growth potential with higher volatility.

Shareholding Pattern

Excellent

Promoter Holding

46.66%

% shares held by company founders/management

Poor

FII Holding

0.00%

% shares held by foreign institutional investors

Poor

DII Holding

0.12%

% held by domestic mutual funds, LIC, banks

Excellent

Promoter Pledged %

0.00%

% of promoter shares pledged as collateral — lower is safer

Growth Engine

Poor

Profit Growth (Quarterly YoY)

5.83%

Net profit growth vs same quarter last year

Poor

Revenue Growth (Quarterly YoY)

10.53%

Revenue growth vs same quarter last year

Poor

Revenue Growth (5-Year CAGR)

4.99%

Compounded annual revenue growth over 5 years

Excellent

EPS Growth (5-Year CAGR)

17.09%

Earnings per share growth over 5 years

Excellent

Net Profit Growth (5-Year CAGR)

16.18%

Compounded annual net profit growth over 5 years

Balance Sheet Health

Excellent

Debt to Equity Ratio

0.01x

Total debt ÷ equity. Below 0.5 = financially healthy

Excellent

Interest Coverage Ratio

105.25x

EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably

Free Cash Flow (5-Year Total)

53.78 (Cr)

Cash left after capex over 5 years. Positive = self-funded growth

Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice

Jenburkt Pharmaceuticals Ltd Fundamental Analysis & Valuation Benchmarking

Educational evaluation of JENBURPH across key market metrics for learning purposes.

Positive Indicators

10 factors identified

Strong Return on Equity (19.87%)

Observation: Efficient use of shareholders' capital generating superior returns.

Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.

Excellent ROCE Performance (27.18%)

Observation: Superior returns on capital employed across business operations.

Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.

Strong Operating Margins (22.75%)

Observation: Healthy 5-year operating margins indicate pricing power and cost control.

Analysis: OPM >15% suggests operational efficiency and competitive advantages.

Attractive Valuation (P/E: 15.33 vs Industry: 31.77)

Observation: Trading at discount to industry peers.

Analysis: P/E below industry average may present value opportunity.

Excellent EPS Growth (17.09% CAGR)

Observation: Outstanding 5-year earnings per share compound growth.

Analysis: EPS CAGR >15% indicates strong wealth creation potential.

Strong Profit Growth Track Record (16.18% CAGR)

Observation: Consistent 5-year profit compound annual growth rate.

Analysis: Profit CAGR >15% demonstrates scalable business model.

Conservative Debt Levels (D/E: 0.01)

Observation: Low leverage provides financial flexibility and reduced risk.

Analysis: Conservative debt structure offers resilience during economic downturns.

Strong Interest Coverage (105.25x)

Observation: Earnings comfortably cover interest obligations.

Analysis: Interest coverage >5x indicates low financial distress risk.

Strong Cash Generation (₹53.78 Cr over 5Y)

Observation: Healthy free cash flow generation supports growth and returns.

Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.

Zero Share Pledging Risk

Observation: No promoter shares pledged as collateral.

Analysis: Absence of share pledging eliminates potential forced-selling pressure.

Risk Factors

2 factors identified

Limited Growth History (4.99% CAGR)

Observation: Below-average 5-year sales growth trajectory.

Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities.

Limited Institutional Interest (FII+DII: 0.12%)

Observation: Low institutional participation may affect liquidity.

Analysis: Limited institutional interest may indicate size constraints or visibility issues.

Jenburkt Pharmaceuticals Ltd vs Pharmaceuticals Peers

Peer Comparison - Pharmaceuticals

Compare Jenburkt Pharmaceuticals Ltd with 10 other companies in the same sector

11 companies
Company Info
Fundamental
Valuation
Profitability
Financial Health
Growth
Dividend
Company
Company name
Score
Bull Run comprehensive fundamental score based on 20+ metrics
Price
Current trading price of the stock
Market Cap
Total value of all shares in the market
P/E
Price per share divided by earnings per share
ROE
Net income divided by shareholder equity
ROCE
Earnings before interest and tax divided by capital employed
Debt/Eq
Total debt divided by total equity
Profit 5Y
Average annual profit growth over 5 years
Sales 5Y
Average annual sales growth over 5 years
Dividend
Annual dividend per share divided by price per share
63.3/100
1142
₹506.05
15.3
Average
19.87%
Good
27.18%
Excellent
0.0
Excellent
16.18%
Excellent
4.99%
Average
1.57%
65.2/100
1844
₹433738.68
37.6
Average
16.86%
Good
20.21%
Excellent
0.1
Excellent
23.78%
Excellent
9.87%
Good
0.89%
67.9/100
6798
₹170445.88
68.6
Average
15.35%
Good
20.44%
Excellent
0.0
Excellent
10.41%
Good
11.65%
Good
0.47%
65.3/100
4538
₹126430.62
58.4
Average
26.52%
Excellent
27.05%
Excellent
0.3
Excellent
13.84%
Good
7.72%
Good
0.86%
Cipla Ltd...
CIPLA500087
59/100
1418
₹123059.76
22.6
Average
17.77%
Good
22.72%
Excellent
0.0
Excellent
28.68%
Excellent
9.97%
Good
0.85%
59.2/100
1319
₹105224.96
18.2
Average
17.96%
Good
22.69%
Excellent
0.2
Excellent
22.28%
Excellent
13.26%
Good
0.63%
Lupin Ltd...
LUPIN500257
66.7/100
2276
₹95148.15
22.0
Average
20.62%
Excellent
21.30%
Excellent
0.3
Excellent
54.88%
Excellent
8.11%
Good
0.58%
68.7/100
957
₹94253.78
18.7
Average
21.21%
Excellent
24.31%
Excellent
0.4
Excellent
25.92%
Excellent
10.27%
Good
1.17%
50.6/100
2420
₹92012.53
52.6
Average
14.68%
Average
15.98%
Good
0.6
Good
11.73%
Good
15.79%
Excellent
0.04%
28.8/100
1436
₹70798.69
20.7
Average
11.08%
Average
14.18%
Average
0.2
Excellent
3.87%
Average
6.55%
Good
0.33%
59.5/100
5452
₹67075.29
28.5
Average
19.39%
Good
20.38%
Excellent
0.2
Excellent
13.93%
Good
9.21%
Good
0.80%

Jenburkt Pharmaceuticals Ltd PE Ratio History

Historical price-to-earnings ratio for JENBURPH — last 5 years

YearEPS (₹)Price (₹)P/E Ratio
FY 202458.86₹1214.7020.6x

P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.

Jenburkt Pharmaceuticals Ltd Dividend History

Annual cash dividends paid by JENBURPH — dividend yield 1.57%

Financial YearDividends Paid (₹ Cr)
FY 20256.78 Cr
FY 20246.32 Cr
FY 20235.50 Cr
FY 20224.68 Cr

Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.

Jenburkt Pharmaceuticals Ltd Quarterly Performance

Latest quarterly metrics for JENBURPH — revenue growth and profit growth vs same quarter last year

Revenue Growth (YoY)

10.53%

Latest quarter vs same quarter previous year

Net Profit Growth (YoY)

5.83%

Latest quarter net profit vs same quarter previous year

5-Year Revenue CAGR

4.99%

Compounded annual revenue growth over 5 years

5-Year Profit CAGR

16.18%

Compounded annual net profit growth over 5 years

Jenburkt Pharmaceuticals Ltd Technical Indicators

SMA 50, SMA 200, RSI and volume signals for JENBURPH — calculated from daily price history

46RSI 14
Neutral — RSI 46

Momentum is balanced — neither overbought nor oversold.

SMA 50
1071
▲ Price above SMA 50 — Short-term bullish
SMA 200
1099
▲ Price above SMA 200 — Long-term uptrend
30-Day Avg Volume
2K shares/day
Average daily traded volume over last 30 trading sessions

Technical indicators are for educational purposes only. Not investment advice.

Jenburkt Pharmaceuticals Ltd Financial Statements

Annual income statement, balance sheet and cash flow for Jenburkt Pharmaceuticals Ltd (JENBURPH) — sourced from NSE/BSE filings.

Loading Financial Statements...

Fetching financial data for Jenburkt Pharmaceuticals Ltd

About JENBURPH (Jenburkt Pharmaceuticals Ltd)

Jenburkt Pharmaceuticals Ltd is a dynamic pharmaceutical company deeply rooted in the Indian healthcare landscape. With a legacy built on innovation and quality, Jenburkt is commit...ted to providing effective and accessible healthcare solutions to address prevalent health challenges. The company's diverse portfolio reflects a dedication to comprehensive patient care, encompassing a wide array of therapeutic segments. Jenburkt prides itself on a robust research and development program, constantly seeking to improve existing therapies and develop novel treatments that meet the evolving needs of the medical community and patients. The company’s core values are grounded in ethical business practices and a strong sense of social responsibility, fostering trust among healthcare professionals and consumers alike. Jenburkt's manufacturing processes adhere to stringent international quality standards, ensuring the safety and efficacy of its products. This dedication to quality is evident in its extensive range of offerings, which span critical therapeutic areas. From managing pain and inflammation to combating infections and metabolic disorders, Jenburkt aims to offer solutions for a broad spectrum of medical conditions. The company’s focus extends beyond prescription medications to include nutraceuticals and consumer healthcare products, reflecting a holistic approach to health and wellness. Driven by a passion for improving lives, Jenburkt continuously strives to expand its reach and impact, making a positive difference in the healthcare journey of individuals across India. Looking forward, Jenburkt Pharmaceuticals is poised for continued growth and innovation. The company is actively exploring new market opportunities and forging strategic partnerships to enhance its product offerings and expand its geographical presence. With a strong foundation built on research, quality, and a commitment to patient well-being, Jenburkt is well-positioned to contribute significantly to the advancement of healthcare in India. The company's leadership remains focused on fostering a culture of innovation and excellence, empowering its team to develop and deliver solutions that meet the evolving needs of the healthcare industry. As a trusted pharmaceutical provider, Jenburkt is dedicated to its mission of making quality healthcare accessible to all.

Company Details

Symbol:JENBURPH
Industry:Pharmaceuticals
Sector:Pharmaceuticals

Key Leadership

Mr. Ashish Uttam Bhuta
Chairman & MD
Mr. Dilip Harkishandas Bhuta
CFO & Whole Time Director
Mr. Ashish Rasiklal Shah
Compliance Officer & Company Secretary

Corporate Events

Recent
Ex-Dividend Date

JENBURPH Share Price: Frequently Asked Questions

What is the current share price of Jenburkt Pharmaceuticals Ltd?

Jenburkt Pharmaceuticals Ltd (JENBURPH) trades at ₹1141.55 on NSE and BSE. Market cap ₹506.05 (Cr). Educational data only.

What is the P/E ratio of Jenburkt Pharmaceuticals Ltd?

Jenburkt Pharmaceuticals Ltd has a P/E of 15.33x vs industry average 31.77x.

What is the Bull Run score for Jenburkt Pharmaceuticals Ltd?

Jenburkt Pharmaceuticals Ltd has a Bull Run score of 63.3/100 based on 25+ financial parameters.

Does Jenburkt Pharmaceuticals Ltd pay dividends?

Jenburkt Pharmaceuticals Ltd has a dividend yield of 1.57%. Past dividends don't guarantee future payments.

What is the ROE of Jenburkt Pharmaceuticals Ltd?

Jenburkt Pharmaceuticals Ltd has ROE of 19.87%. Higher ROE indicates better use of shareholder equity.

What is the debt-to-equity ratio of Jenburkt Pharmaceuticals Ltd?

Jenburkt Pharmaceuticals Ltd has debt-to-equity of 0.01.

Is Jenburkt Pharmaceuticals Ltd a good investment?

Bull Run gives Jenburkt Pharmaceuticals Ltd a score of 63.3/100. This is not investment advice — consult a SEBI-registered advisor.